Under construction – not a live service
Sign in
Taking people in JapanNo phase

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Key facts

Where
Tokyo, JapanSee the site

Where in Japan

  • TokyoTokyo, JapanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Takeda
Trial code
NCT06461533
Record updated
7 August 2026
Original description
This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.Read full original descriptionShow less

General Use-results Survey of OBIZUR for I.V. Injection (All-case Surveillance)

This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Susoctocog Alfa (Genetical Recombination) intravenous injection and to check if Susoctocog Alfa (Genetical Recombination) intravenous injection improves bleeding events of AHA.

During the study, participants with AHA will take Susoctocog Alfa (Genetical Recombination) intravenous injection according to their clinic's standard practice. The study doctors will check for side effects from Susoctocog Alfa (Genetical Recombination) intravenous injection for up to 90 days after the last dose of study drug or until discontinued (varied from participant to participant).

Inclusion: All participants with Acquired Haemophilia A, treated with Susoctocog Alfa (Genetical Recombination).

Exclusion: None.

ClinicalTrials.gov NCT06461533

Under construction, not live – A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A (NCT06461533) – Frontlight Research